Results from phase 3 CEPHEUS study are out - MSK Department of Medicine

Results from phase 3 CEPHEUS study are out – MSK Department of Medicine

MSK Department of Medicine shared a post on X about a recent paper by Saad Usmani et al. published in Nature Medicine:

“A phase 3 clinical trial led by Saad Usmani found that a combination of four therapies significantly improved outcomes for people with newly diagnosed multiple myeloma who were not eligible for a transplant. Learn more.”

“Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study”

Authors: Saad Usmani, Thierry Facon, Vania Hungria, Robin Carson, Sonja Zweegman et al.

Results from phase 3 CEPHEUS study are out - MSK Department of Medicine

More posts featuring MSK Department of Medicine.

cancer CEPHEUS MSK Department of Medicine multiple myeloma OncoDaily Oncology Robin Carson Saad Usmani Sonja Zweegman Thierry Facon Vania Hungria